Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Interest & Investment Income (2016 - 2017)

IGC Pharma has reported Interest & Investment Income over the past 8 years, most recently at $100.0 for Q3 2017.

  • Quarterly Interest & Investment Income fell 12.28% to $100.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $2228.0 through Sep 2017, up 1.36% year-over-year, with the annual reading at $1744.0 for FY2017, 16.35% down from the prior year.
  • Interest & Investment Income was $100.0 for Q3 2017 at IGC Pharma, down from $114.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $27509.0 in Q1 2013 and troughed at $70.0 in Q4 2015.
  • The 5-year median for Interest & Investment Income is $1919.0 (2013), against an average of $3572.3.
  • Year-over-year, Interest & Investment Income skyrocketed 387.46% in 2013 and then plummeted 95.65% in 2015.
  • A 5-year view of Interest & Investment Income shows it stood at $1824.0 in 2013, then fell by 11.73% to $1610.0 in 2014, then plummeted by 95.65% to $70.0 in 2015, then skyrocketed by 62.86% to $114.0 in 2016, then dropped by 12.28% to $100.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Interest & Investment Income are $100.0 (Q3 2017), $114.0 (Q3 2016), and $2014.0 (Q1 2016).